Clinical investigators and the pharmaceutical industry

New England Journal of Medicine

Volumn 342, Issue 20, 2000, Pages 1539-1544

  Bodenheimer, Thomas ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; PRIORITY JOURNAL; REVIEW; ARTICLE; BIOMEDICAL AND BEHAVIORAL RESEARCH; CLINICAL TRIAL; CONFLICT OF INTEREST; CONTRACT; DRUG APPROVAL; DRUG SCREENING; ECONOMICS; FINANCIAL MANAGEMENT; INTERPERSONAL COMMUNICATION; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; PUBLIC RELATIONS; PUBLISHING; SOCIAL CHANGE; UNITED STATES; UNIVERSITY HOSPITAL; WRITING;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

ACADEMIC MEDICAL CENTERS; AUTHORSHIP; BIOMEDICAL RESEARCH; CLINICAL TRIALS; CONFLICT OF INTEREST; CONTRACTS; DISCLOSURE; DRUG APPROVAL; DRUG EVALUATION; DRUG INDUSTRY; INTERINSTITUTIONAL RELATIONS; PUBLISHING; RESEARCH SUPPORT; SOCIAL CHANGE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0034682156     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200005183422024     Document Type: Review

References (37)

1. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 1998;338: 101-6.
2. Davidson RA. Source of funding and outcome of clinical trials. J Gen Intern Med 1986;1:155-8.
3. Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med 1996;124:485-9.
4. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999;282:1453-7.
5. Chow S-C, Liu J-P. Design and analysis of clinical trials. New York: John Wiley, 1998.
6. Spilker BA. The drug development and approval process. (See: http:// www.phrma.org.)
7. Psaty BM, Weiss NS, Furberg CD, et al. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 1999;282:786-90.
8. Mathieu MP, ed. Parexel's pharmaceutical R & D statistical sourcebook 1998. Waltham, Mass.: Parexel International Corporation, 1999.
9. An industry in evolution. Boston: Centerwatch, 1999.
10. Woodward B. Challenges to human subject protections in US medical research. JAMA 1999;282:1947-52.
11. From bench to bedside: preserving the research mission of academic health centers. New York: Commonwealth Fund, 1999.
12. CRO mergers bring mixed results. Centerwatch 1997;4(6):1, 9-16.
13. Henderson L. The ups and downs of SMO usage. Centerwatch 1999; 6(5):1, 4-8.
14. Getz KA. AMCs rekindling clinical research partnerships with industry. Boston: Centerwatch, 1999.
15. Vogel JR. Maximizing the benefits of SMOs. Appl Clin Trials 1999; 8(11):56-62.
16. Academic medical centers: slowly turning the tide. Centerwatch 1997; 4(6):1-8.
17. Bero LA, Rennie D. Influences on the quality of published drug studies. Int J Technol Assess Health Care 1996;12(2):209-37.
18. Rochon PA, Berger PB, Gordon M. The evolution of clinical trials: inclusion and representation. CMAJ 1998;159:1373-4.
19. Rochon PA, Gurwitz JH, Simms RW, et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 1994;154:157-63.
20. Johansen HK, Gotzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999; 282:1752-9.
21. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999;282:790-5.
22. Blumenthal D, Campbell EG, Anderson MS, Causino N, Louis KS. Withholding research results in academic life science: evidence from a national survey of faculty. JAMA 1997;277:1224-8.
23. Chalmers I. Underreporting research is scientific misconduct. JAMA 1990;263:1405-8.
24. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417-23.
25. Phillips RA, Hoey J. Constraints of interest: lessons at the Hospital for Sick Children. CMAJ 1998;159:955-7. [Erratum, CMAJ 1998;159: 1244.]
26. Rennie D. Thyroid storm. JAMA 1997;277:1238-43.
27. Applegate WB, Furberg CD, Byington RP, Grimm R Jr. The Multicenter Isradipine Diuretic Atherosclerosis Study. JAMA 1997;277:297.
28. Levy D. Ghostwriters a hidden resource for drug makers. USA Today. September 25, 1996.
29. Larkin M. Whose article is it anyway? Lancet 1999;354:136.
30. Ghost with a chance in publishing undergrowth. Lancet 1993;342: 1498-9
31. Rennie D, Flanagin A. Authorship! Authorship! Guests, ghosts, grafters, and the two sided coin. JAMA 1994;271:469-71.
32. Brennan TA. Buying editorials. N Engl J Med 1994;331:673-5.
33. Flanagin A, Carey LA, Fontanarosa PB, et al. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journais. JAMA 1998;280:222-4.
34. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. JAMA 1997; 277:927-34. [Erratum, JAMA 1998;279:510.]
35. Wood AJJ, Stein CM, Woosley R. Making medicines safer - the need for an independent drug safety board. N Engl J Med 1998;339:1851-4.
36. Kunin CM. Clinical investigators and the pharmaceutical industry. Ann Intern Med 1978;89:Suppl:842-5.
37. Shine KI. Some imperatives for clinical research. JAMA 1997;278: 245-6.